Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 54,988 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Obstructive Sleep Apnea, Atrial Fibrillation
Interventions: Cardiac Ablation for Atrial Fibrillation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Redwood City, California

Conditions: HIV/AIDS
Interventions: Patient Navigation, Usual Care; Behavioral · Other
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Comparative Genomic Hybridization, Laboratory Biomarker Analysis, Polymerase Chain Reaction; Genetic · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nausea, Vomiting
Interventions: Glycopyrrolate, Normal Saline; Drug
Lead sponsor: Kokila N Thenuwara; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Schizophrenia
Interventions: TV-44749, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 38 more

Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Interventions: Palliative Care, Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abdominal Pain
Interventions: Enterra; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: SUPPORT, Currently Available Printed Material; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Impairment
Interventions: bevenopran; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 18 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Neuroendocrine Tumors
Interventions: Lithium Carbonate; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colorectal Cancer
Interventions: Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day, Irinotecan, Oxaliplatin, Surgery, Folinic Acid, Fluorouracil; Radiation · Drug · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • Harvey, Illinois + 2 more

Conditions: Neuroblastoma, Medulloblastoma, Relapse
Interventions: TPI 287; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 12 Months to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more

Conditions: Cardiogenic Shock, Bradycardia, Shock
Interventions: Backup Pacing Rate Change; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Plaque Psoriasis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 59
States / cities: Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more

Conditions: Thyroid Carcinoma
Interventions: LBH589; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Interventions: Not listed
Lead sponsor: University of South Carolina; Other
Eligibility: 20 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Interventions: Vector ventilator, Resmon Pro; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Head and Neck Cancer, Dental Disease, Xerostomia, Osteoradionecrosis
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Farmington, Connecticut • Boston, Massachusetts • New York, New York + 3 more

Conditions: Advanced Cancer
Interventions: DM-CHOC-PEN; Drug
Lead sponsor: DEKK-TEC, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: VPD Implant System; Device
Lead sponsor: CardioKinetix, Inc; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Asheville, North Carolina + 3 more

Conditions: Atrial Fibrillation, Arrhythmia, Stroke, Cardiovascular
Interventions: The Lifestar Act III; Device
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Allosensitization, Heart Transplant Failure and Rejection
Interventions: Daratumumab-SC; Drug
Lead sponsor: Ronald Witteles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Plasma Cell Myeloma, Transplant-Related Carcinoma
Interventions: Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Effects of PAP on Afib Recurrence Risk After Catheter Ablation in OSA Patients

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

Research Study in Patients With Advanced Ovarian Epithelial Cancer

Minimizing Nausea and Vomiting During Spinals for CS

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Gastric Electrical Stimulation for Abdominal Pain in Gastroparesis

Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

Lithium for Low-Grade Neuroendocrine Tumors

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Augmented Pacing for Shock in the Cardiac Intensive Care Unit

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Trial of LBH589 in Metastatic Thyroid Cancer

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients

Observational Study of Dental Outcomes in Head and Neck Cancer Patients

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"

Guideline Directed Medical Therapy in Patients With Heart Failure

Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients

Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma